Immunovia AB (publ) (IMMNOV.ST)
SEK 0.66
(1.23%)
SEK 0.66
(1.23%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -5.1 Million SEK | -66.57% |
| 2022 | -3.06 Million SEK | -119.39% |
| 2021 | 15.81 Million SEK | -60.84% |
| 2020 | 40.38 Million SEK | 49.17% |
| 2019 | 27.07 Million SEK | 6.65% |
| 2018 | 25.38 Million SEK | 4.94% |
| 2017 | 24.18 Million SEK | -1.15% |
| 2016 | 24.46 Million SEK | 43.97% |
| 2015 | 16.99 Million SEK | 345.44% |
| 2014 | -6.92 Million SEK | -1217.12% |
| 2013 | -525.75 Thousand SEK | -3002.34% |
| 2012 | 18.11 Thousand SEK | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 156 Thousand SEK | 100.7% |
| 2024 Q2 | -23.97 Million SEK | -45.51% |
| 2023 FY | -5.1 Million SEK | -66.57% |
| 2023 Q2 | -5.08 Million SEK | -880.35% |
| 2023 Q1 | -519 Thousand SEK | -22.7% |
| 2023 Q3 | 344 Thousand SEK | 106.76% |
| 2023 Q4 | -22.31 Million SEK | -6587.21% |
| 2022 Q3 | -1.09 Million SEK | -130.67% |
| 2022 FY | -3.06 Million SEK | -119.39% |
| 2022 Q4 | -423 Thousand SEK | 61.48% |
| 2022 Q2 | -476 Thousand SEK | 55.51% |
| 2022 Q1 | -1.07 Million SEK | -93.14% |
| 2021 Q3 | -2.29 Million SEK | -129.34% |
| 2021 Q1 | 10.83 Million SEK | 10.55% |
| 2021 Q2 | 7.82 Million SEK | -27.74% |
| 2021 FY | 15.81 Million SEK | -60.84% |
| 2021 Q4 | -554 Thousand SEK | 75.88% |
| 2020 FY | 40.38 Million SEK | 49.17% |
| 2020 Q1 | 11.28 Million SEK | 38.1% |
| 2020 Q2 | 11.16 Million SEK | -1.05% |
| 2020 Q4 | 9.8 Million SEK | 20.48% |
| 2020 Q3 | 8.13 Million SEK | -27.15% |
| 2019 Q2 | 6.35 Million SEK | 5.76% |
| 2019 Q4 | 8.17 Million SEK | 24.92% |
| 2019 Q1 | 6 Million SEK | 13.02% |
| 2019 FY | 27.07 Million SEK | 6.65% |
| 2019 Q3 | 6.54 Million SEK | 2.93% |
| 2018 FY | 25.38 Million SEK | 4.94% |
| 2018 Q4 | 5.31 Million SEK | -22.06% |
| 2018 Q3 | 6.82 Million SEK | -1.52% |
| 2018 Q1 | 6.32 Million SEK | -25.68% |
| 2018 Q2 | 6.92 Million SEK | 9.5% |
| 2017 Q1 | 5.55 Million SEK | -24.37% |
| 2017 FY | 24.18 Million SEK | -1.15% |
| 2017 Q4 | 8.5 Million SEK | 88.83% |
| 2017 Q3 | 4.5 Million SEK | -19.84% |
| 2017 Q2 | 5.62 Million SEK | 1.19% |
| 2016 Q3 | 5.17 Million SEK | -23.46% |
| 2016 Q4 | 7.34 Million SEK | 41.93% |
| 2016 FY | 24.46 Million SEK | 43.97% |
| 2016 Q2 | 6.76 Million SEK | -34.85% |
| 2016 Q1 | 10.37 Million SEK | 1486.29% |
| 2015 FY | 16.99 Million SEK | 345.44% |
| 2015 Q4 | 654.23 Thousand SEK | 0.0% |
| 2015 Q1 | -583 Thousand SEK | 74.43% |
| 2015 Q3 | 654.23 Thousand SEK | 212.22% |
| 2015 Q2 | -583 Thousand SEK | 0.0% |
| 2014 Q4 | -2.28 Million SEK | 0.0% |
| 2014 Q1 | -1.18 Million SEK | 0.0% |
| 2014 Q2 | -1.18 Million SEK | 0.0% |
| 2014 Q3 | -2.28 Million SEK | -92.83% |
| 2014 FY | -6.92 Million SEK | -1217.12% |
| 2013 FY | -525.75 Thousand SEK | -3002.34% |
| 2012 FY | 18.11 Thousand SEK | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AroCell AB (publ) | -2.1 Million SEK | -142.959% |
| Devyser Diagnostics AB (publ) | 148.1 Million SEK | 103.448% |
| Prostatype Genomics AB (publ) | -18.09 Million SEK | 71.769% |
| SenzaGen AB | 34.93 Million SEK | 114.62% |
| Spermosens AB | -169 Thousand SEK | -2921.893% |